Sontuzumab
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer[1].
Product Specifications
CAS Number
372075-37-1
Product Name Alternative
AS1402; huHMFG-1
UNSPSC
12352203
Target
Mucin
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sontuzumab.html
Purity
99.66
Solubility
H2O
Smiles
[Sontuzumab]
Molecular Weight
(145.38 kDa)
References & Citations
[1]Pegram MD, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11 (5) :R73.|[2]Snijdewint FG, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer. 2001 Jul 1;93 (1) :97-106.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![DiOC3 (3) iodide [3,3-Dipropyloxacarbocyanine iodide]](https://cdn.genprice.uk/products/271/7361093/imageurl/22039-aat.webp)
22039-AAT 25 mg
DiOC3 (3) iodide [3,3-Dipropyloxacarbocyanine iodide]
Sign In for Pricing
View Details 
BNC741860-500 1x 500 µL
MUC16 / CA125 (Ovarian Carcinoma Marker) (MUC16/1860), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details